Recherche intégrée pour une médecine personnalisée en oncologie digestive : M. Ychou/A. Thierry

Liste des Publications

Verkarre V, Bibeau F [The inherited cancers, the pathologist]. Ann Pathol. 2020;40(2):61-62. doi:10.1016/j.annpat.2020.02.016

Adenis A, Samalin E, Mazard T, Portales F, Mourregot A, Ychou M [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?]. Bull Cancer. Jan 21, 2020. doi:10.1016/j.bulcan.2019.12.005

Nougaret S, Monsonis B, Molinari N, Piron L, Kassam Z, Cassinotto C, Guiu B Quantification of liver fat content in liver and primary liver lesions using triple-echo-gradient-echo MRI. Eur Radiol. 2020-4-22. doi:10.1007/s00330-020-06757-1

Delattre J-F, Cohen R, Henriques J, Falcoz A, Emile J-F, Fratte S, Chibaudel B, Dauba J, Dupuis O, Bécouarn Y, Bibeau F, Taieb J, Louvet C, Vernerey D, André T, Svrcek M Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). JCO. 2020-03-13. doi:10.1200/JCO.19.01960

Maciel C, Bharwani N, Kubik-Huch R, Manganaro L, Otero-Garcia M, Nougaret S, Alt C, Cunha T, Forstner R MRI of female genital tract congenital anomalies: European Society of Urogenital Radiology (ESUR) guidelines. Eur Radiol. 2020-3-27. doi:10.1007/s00330-020-06750-8

Bibeau F, Léger A, Bazille C, Selves J Les cancers colorectaux héréditaires vus par le pathologiste. Annales de Pathologie. 2020;40(2):105-113. doi:10.1016/j.annpat.2020.02.017

Beer L, Sahin H, Bateman N, Blazic I, Vargas H, Veeraraghavan H, Kirby J, Fevrier-Sullivan B, Freymann J, Jaffe C, Brenton J, Nougaret S, Darcy K, Maxwell G, Conrads T, Huang E, Sala E Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis. Eur Radiol. 2020-4-6. doi:10.1007/s00330-020-06755-3

Abraham J-D, Al Amir Dache Z, Khalyfa A, Jariel-Encontre I, Forné T, Prévostel C, Chouaib S, Gozal D, Thierry A Hypoxia differently modulates the release of mitochondrial and nuclear DNA. Br. J. Cancer. Jan 13, 2020. doi:10.1038/s41416-019-0716-y

Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg R, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt C, Saltz L, Saunders M, Schmoll H-J, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner A, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, André T Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. European Journal of Cancer. 2020;130. doi:10.1016/j.ejca.2020.02.009

Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy P-J, Guiu S BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. Cancers. 2020;12(4):828. doi:10.3390/cancers12040828

Al Amir Dache Z, Otandault A, Tanos R, Pastor B, Meddeb R, Sanchez C, Arena G, Lasorsa L, Bennett A, Grange T, El Messaoudi S, Mazard T, Thierry A Blood contains circulating cell-free respiratory competent mitochondria. FASEB J.. Jan 19, 2020. doi:10.1096/fj.201901917RR

Hofman P, Dagher G, Laurent-Puig P, Hugo-Marquette C, Barlesi F, Bibeau F, Clément B [Tumor banks and complex data management: Current and future challenges]. Ann Pathol. Feb 25, 2019. doi:10.1016/j.annpat.2019.01.017

Riou O, Valdenaire S, Debuire P, Fenoglietto P, Debrigode C, Mazard T, Assenat É, Azria D [Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?]. Cancer Radiother. Aug 20, 2019. doi:10.1016/j.canrad.2019.07.159

Bibeau F [Biomarker, what is the pathologist's role?]. Ann Pathol. 2019;39(3):177-178. doi:10.1016/j.annpat.2019.05.002

Badoual C, Bibeau F [Augmented pathology, future or present ?]. Ann Pathol. Mar 14, 2019. doi:10.1016/j.annpat.2019.02.009

Charton E, Cuer B, Cottone F, Efficace F, Touraine C, Hamidou Z, Fiteni F, Bonnetain F, Woronoff-Lemsi M-C, Bascoul-Mollevi C, Anota A Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review. Qual Life Res. Nov 27, 2019. doi:10.1007/s11136-019-02367-7

Assenat E, Langlois-Jacques C, Glehen O, Soulé J, Payen L, Kepenekian V, Dupuy M, Belouin F, Morency E, Saywell V, Flacelière M, Elies P, Liaud P, Mazard T, Maucort-Boulch D, Tan W, Vire B, Villeneuve L, Ychou M, Kohli M, Joubert D, Prieur A The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine. 2019;51. doi:10.1016/j.ebiom.2019.11.035

Lutz M, Zalcberg J, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch H, Laurent-Puig P, Lordick F, Möhler M, Mönig S, Obermannova R, Piessen G, Riddell A, Röcken C, Roviello F, Schneider P, Seewald S, Smyth E, van Cutsem E, Verheij M, Wagner A, Otto F The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur. J. Cancer. 2019;112. doi:10.1016/j.ejca.2019.01.106

Assenat E, Pageaux G-P, Peron J-M, Bécouarn Y, Seitz J-F, Merle P, Blanc J-F, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Br. J. Cancer. Apr 04, 2019. doi:10.1038/s41416-019-0443-4

Nougaret S, Jhaveri K, Kassam Z, Lall C, Kim D Rectal cancer MR staging: pearls and pitfalls at baseline examination. Abdom Radiol (NY). May 21, 2019. doi:10.1007/s00261-019-02024-0

Hope T, Gollub M, Arya S, Bates D, Ganeshan D, Harisinghani M, Jhaveri K, Kassam Z, Kim D, Korngold E, Lalwani N, Moreno C, Nougaret S, Paroder V, Paspulati R, Golia Pernicka J, Petkovska I, Pickhardt P, Rauch G, Rosenthal M, Sheedy S, Horvat N Rectal cancer lexicon: consensus statement from the society of abdominal radiology rectal & anal cancer disease-focused panel. Abdom Radiol (NY). Aug 06, 2019. doi:10.1007/s00261-019-02170-5

Lucidarme O, Wagner M, Gillard P, Kim S, Bachet J-B, Rousseau B, Mazard T, Louvet C, Chibaudel B, Cohen R, Garcia-Larnicol M-L, Gobert A, Henriques J, André T RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study. Cancer Imaging. 2019;19(1):85. doi:10.1186/s40644-019-0271-z

Otandault A, Anker P, Al Amir Dache Z, Guillaumon V, Meddeb R, Pastor B, Pisareva E, Sanchez C, Tanos R, Tousch G, Schwarzenbach H, Thierry A Recent advances in Circulating Nucleic Acids in oncology. Ann. Oncol.. Feb 07, 2019. doi:10.1093/annonc/mdz031

Mazard T, Assenat E, Dupuy M, Mollevi C, René A, Adenis A, Chauffert B, Boucher E, Francois E, Pierga J-Y, Ducreux M, Ychou M, Gallix B Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. Dig Liver Dis. May 10, 2019. doi:10.1016/j.dld.2019.03.028

Meddeb R, Dache Z, Thezenas S, Otandault A, Tanos R, Pastor B, Sanchez C, Azzi J, Tousch G, Azan S, Mollevi C, Adenis A, El Messaoudi S, Blache P, Thierry A Quantifying circulating cell-free DNA in humans. Sci Rep. 2019;9(1):5220. doi:10.1038/s41598-019-41593-4

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés